Raman spectroscopy for glutathione measurements in Mycobacterium tuberculosis strains with different antibiotic resistance

Author(s):  
Andrey Zyubin ◽  
Anastasia Lavrova ◽  
Olga Manicheva ◽  
Marine Dogonadze ◽  
Vitaly Belik ◽  
...  
2021 ◽  
Author(s):  
Andrey Y. Zyubin ◽  
Anastasia Lavrova ◽  
Eugenie Postnicov ◽  
Olga Manicheva ◽  
Marine Dogonadze ◽  
...  

Data in Brief ◽  
2018 ◽  
Vol 21 ◽  
pp. 2430-2434
Author(s):  
Andrey Zyubin ◽  
Anastasia Lavrova ◽  
Olga Manicheva ◽  
Marine Dogonadze ◽  
Ilia Samusev

FEBS Journal ◽  
2016 ◽  
Vol 283 (12) ◽  
pp. 2206-2218 ◽  
Author(s):  
Ekaterina V. Filippova ◽  
Karen J. Kieser ◽  
Chi-Hao Luan ◽  
Zdzislaw Wawrzak ◽  
Olga Kiryukhina ◽  
...  

Author(s):  
Vincent O. Baron ◽  
Mingzhou Chen ◽  
Simon O. Clark ◽  
Ann Williams ◽  
Kishan Dholakia ◽  
...  

PeerJ ◽  
2018 ◽  
Vol 6 ◽  
pp. e5895 ◽  
Author(s):  
Thomas Andreas Kohl ◽  
Christian Utpatel ◽  
Viola Schleusener ◽  
Maria Rosaria De Filippo ◽  
Patrick Beckert ◽  
...  

Analyzing whole-genome sequencing data of Mycobacterium tuberculosis complex (MTBC) isolates in a standardized workflow enables both comprehensive antibiotic resistance profiling and outbreak surveillance with highest resolution up to the identification of recent transmission chains. Here, we present MTBseq, a bioinformatics pipeline for next-generation genome sequence data analysis of MTBC isolates. Employing a reference mapping based workflow, MTBseq reports detected variant positions annotated with known association to antibiotic resistance and performs a lineage classification based on phylogenetic single nucleotide polymorphisms (SNPs). When comparing multiple datasets, MTBseq provides a joint list of variants and a FASTA alignment of SNP positions for use in phylogenomic analysis, and identifies groups of related isolates. The pipeline is customizable, expandable and can be used on a desktop computer or laptop without any internet connection, ensuring mobile usage and data security. MTBseq and accompanying documentation is available from https://github.com/ngs-fzb/MTBseq_source.


2019 ◽  
Vol 133 (12) ◽  
pp. 1271-1280 ◽  
Author(s):  
Stefan H. Oehlers

Abstract The spectre of the coming post-antibiotic age demands novel therapies for infectious diseases. Tuberculosis (TB), caused by Mycobacterium tuberculosis, is the single deadliest infection throughout human history. M. tuberculosis has acquired antibiotic resistance at an alarming rate with some strains reported as being totally drug resistant. Host-directed therapies (HDTs) attempt to overcome the evolution of antibiotic resistance by targeting relatively immutable host processes. Here, I hypothesise the induction of hypoxia via anti-angiogenic therapy will be an efficacious HDT against TB. I argue that anti-angiogenic therapy is a modernisation of industrial revolution era sanatoria treatment for TB, and present a view of the TB granuloma as a ‘bacterial tumour’ that can be treated with anti-angiogenic therapies to reduce bacterial burden and spare host immunopathology. I suggest two complementary modes of action, induction of bacterial dormancy and activation of host hypoxia-induced factor (HIF)-mediated immunity, and define the experimental tools necessary to test this hypothesis.


Sign in / Sign up

Export Citation Format

Share Document